Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort

Hu, Chao; Li, Siting; Xie, Zhibo; You, Hanxiao; Jiang, Hui; Shi, Yu; Qi, Wanting; Zhao, Jiuliang; Wang, Qian; Tian, Xin; Li, Mengtao; Zhao, Yan; Zeng, Xiaofeng

doi:10.3389/fimmu.2021.648881

Cited by 12 publications

(8 citation statements)

References 30 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another limitation might be related to the laboratory methods used to test the aPLs, as there are constant discussions over the need for the standardization of APS tests, and the last updated guidelines included a mixing test for LA detection [31]. Even so, the kits used in our laboratory of immunology were among the assays tested and recommended for the APS assessment [32,33]. We do not present data about the persistence of aPLs for more than 12 weeks.…”

Section: Discussionmentioning

confidence: 95%

Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis

et al. 2023

View full text Add to dashboard Cite

We sought to determine the prevalence of antiphospholipid antibodies (aPLs) and their correlation with COVID-19 severity (in terms of clinical and laboratory parameters) in patients without thrombotic events during the early phase of infection. This was a cross-sectional study with the inclusion of hospitalized COVID-19 patients from a single department during the COVID-19 pandemic (April 2020–May 2021). Previous known immune disease or thrombophilia along with long-term anticoagulation and patients with overt arterial or venous thrombosis during SARS-CoV-2 infection were excluded. In all cases, data on four criteria for aPL were collected, namely lupus anticoagulant (LA), IgM and IgG anticardiolipin antibodies (aCL), as well as IgG anti-β2 glycoprotein I antibodies (aβ2GPI). One hundred and seventy-nine COVID-19 patients were included, with a mean age of 59.6 (14.5) years and a sex ratio of 0.8 male: female. LA was positive in 41.9%, while it was strongly positive in 4.5%; aCL IgM was found in 9.5%, aCL IgG in 4.5%, and aβ2GPI IgG in 1.7% of the sera tested. Clinical correlation: LA was more frequently expressed in severe COVID-19 cases than in moderate or mild cases (p = 0.027). Laboratory correlation: In univariate analysis, LA levels were correlated with D-dimer (p = 0.016), aPTT (p = 0.001), ferritin (p = 0.012), C-reactive protein (CRP) (p = 0.027), lymphocyte (p = 0.040), and platelet (p < 0.001) counts. However, in the multivariate analysis, only the CRP levels correlated with LA positivity: OR (95% CI) 1.008 (1.001–1.016), p = 0.042. LA was the most common aPL identified in the acute phase of COVID-19 and was correlated with infection severity in patients without overt thrombosis.

show abstract

Section: Discussionmentioning

confidence: 95%

Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Complications leading to thrombophilia were also involved in the exclusion criteria, which might prevent some elderly patients from entering our cohort. In addition, differences in the age distribution pattern of APS between ethnic groups were suspected, since previous studies reported a younger APS population from East Asia than that from Europe ( 20 , 21 ). A larger study should be expected to investigate the role of age in the prognosis of ptAPS.…”

Section: Discussionmentioning

confidence: 99%

Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome

Huang

Liu

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

ObjectivesThis study aimed to investigate whether there are sex differences in clinical characteristics and prognosis in patients with primary thrombotic antiphospholipid syndrome (ptAPS).MethodsFrom January 2013 to July 2021, 154 consecutive patients diagnosed with ptAPS were prospectively recruited. Multivariable Cox regression was used to evaluate the association between gender and the composite endpoint including thromboembolic recurrence or all-cause death during follow-up.ResultsTotally, 80 (52%) male and 74 (48%) female patients with ptAPS were included, and men had a higher percentage of smokers/ex-smokers [50 (62%) vs. 6 (8%), p < 0.001] and hyperhomocysteinemia [26 (32%) vs. 9 (12%), p = 0.003]. The baseline thromboembolic events were similar in two genders, except for limb ischemia [15 (19%) in men vs. 1 (1%) in women, p < 0.001]. During a median follow-up of 42 months, the composite endpoint occurred in 30 (38%) male and 15 (20%) female patients (p = 0.019). Male gender [HR 2.499, 95% CI (1.316, 4.743), p = 0.005] and warfarin administration [HR 0.482, 95% CI (0.257, 0.905), p = 0.023] remained independent risk factors for the composite endpoint. Male gender [HR 3.699, 95% CI (1.699, 8.246), p = 0.001] and isolated lupus anticoagulant positivity [HR 2.236, 95% CI (1.039, 4.811), p = 0.040] were independent risk factors for thromboembolic recurrence.ConclusionThere are sex disparities in the clinical characteristics in patients with ptAPS and the male gender is an independent risk factor for the poor prognosis. Male patients with isolated lupus anticoagulant (LA) positivity have the highest risk of thromboembolic recurrence.

show abstract

“…First, autoantibodies in patients with RA are heterogeneous, having different affinities, subtypes, and glycosylation patterns. Second, technical aspects of the assays varied, including cut-off values, methods of calibration and quantitation, choice of solid phase and coating, and type and source of antigen ( 23 ). Last, the performance of different detection methods may be influenced by antigen epitopes (linear epitopes, spatial conformation epitopes).…”

Section: Discussionmentioning

confidence: 99%

Comparison of different assays for the detection of anticyclic citrullinated peptide antibodies in patients with rheumatoid arthritis

Wang

Chen

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveTo evaluate a novel fully automated immunoturbidimetric assay developed by Qiangsheng Biotechnology Company for the detection of anticyclic citrullinated peptide antibodies (anti-CCP) in serum of patients with rheumatoid arthritis (RA) and compare it to the conventional EUROIMMUN- anti-CCP ELISA. Two other commonly used automated assays, the Elecsys anti-CCP assay, an ECLIA that is run on the Modular Analystics E170 (Cobas Diagnostics, Germany), and an anti-CCP CLIA developed by YHLO that is run on the iFlash 3000 Chemiluminescence Immunoassay Analyzer, were included as reference standards.MethodsA total of 264 serum samples were collected from patients attending the First People’s Hospital of Wenling affiliated to Wenzhou Medical University between July 2020 and November 2020. These included 131 serum samples collected from patients with RA, 70 serum samples collected from patients with other autoimmune diseases, and 63 serum samples collected from healthy controls at a physical examination. The clinical performance and sensitivity and specificity of the four anti-CCP assays for the diagnosis of RA were compared using receiver operating characteristic (ROC) curve analysis.ResultsThe Kappa statistic indicated almost perfect agreement between the EUROIMMUN-anti-CCP ELISA and the Elecsys anti-CCP ECLIA (Cobas) (0.863), the EUROIMMUN-anti-CCP ELISA and the anti-CCP CLIA (YHLO) (0.862), and the Elecsys anti-CCP ECLIA (Cobas) and the anti-CCP CLIA (YHLO) (0.816). On ROC curve analysis, AUC values were 0.955 for the EUROIMMUN-anti-CCP ELISA, 0.948 for the anti-CCP CLIA (YHLO), 0.947 for the Elecsys anti-CCP ECLIA (Cobas) and 0.903 for Qiangsheng, indicating all the assays had a good diagnostic performance for RA.ConclusionThe anti-CCP assays provided similar diagnostic information. The novel fully automated immunoturbidimetric assay for anti-CCP developed by Qiangsheng Biotechnology Company may be especially useful for large scale clinical screening in RA as it has a shorter testing time than the commercially available alternatives.

show abstract

Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort

Cited by 12 publications

References 30 publications

Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis

Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis

Sex Differences in Clinical Characteristics and Prognosis in Primary Thrombotic Antiphospholipid Syndrome

Comparison of different assays for the detection of anticyclic citrullinated peptide antibodies in patients with rheumatoid arthritis

Contact Info

Product

Resources

About